ABBOTINDIA:NSE:NSE-Abbott India Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 31448.1

Change

-91.80 (-0.29)%

Market Cap

USD 633.57B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-1.15 (-0.02%)

USD 1,513.85B
CIPLA:NSE Cipla Limited

+17.95 (+1.28%)

USD 1,191.84B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+48.45 (+1.65%)

USD 1,023.22B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+6.25 (+0.56%)

USD 970.36B
MANKIND:NSE Mankind Pharma Ltd

+4.05 (+0.18%)

USD 960.38B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+15.80 (+1.81%)

USD 890.87B
LUPIN:NSE Lupin Limited

+56.90 (+2.91%)

USD 868.96B
AUROPHARMA:NSE Aurobindo Pharma Limited

+41.25 (+3.92%)

USD 639.93B
ALKEM:NSE Alkem Laboratories Limited

+81.85 (+1.77%)

USD 593.38B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+53.75 (+4.03%)

USD 373.94B

ETFs Containing ABBOTINDIA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.76% 98% N/A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.76% 98% N/A 95% A
Trailing 12 Months  
Capital Gain 15.10% 65% D 76% C+
Dividend Return 1.50% 93% A 79% B-
Total Return 16.60% 65% D 76% C+
Trailing 5 Years  
Capital Gain 101.73% 33% F 33% F
Dividend Return 7.46% 65% D 44% F
Total Return 109.19% 33% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain 15.84% 27% F 26% F
Dividend Return 16.76% 28% F 27% F
Total Return 0.91% 75% C 60% D-
Risk Return Profile  
Volatility (Standard Deviation) 12.53% 100% F 95% A
Risk Adjusted Return 133.72% 99% N/A 95% A
Market Capitalization 633.57B 90% A- 93% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector